Navigation Links
RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease
Date:11/10/2008

r's Consortium partners, has been designated by the National Institutes of Health as one of just 31 Alzheimer's disease Centers in the nation.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. International Steering Committee for RVX-208 IVUS Trial Formed
2. Phase 1b/2a Program Commences for RVX-208
3. Industry Leaders Select Resverlogixs RVX-208
4. Dosing for RVX-208 Phase 1a Clinical Study Completed
5. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
6. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
7. deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke
8. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
9. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
10. New Study Shares Best Practices in Biopharma Public Relations
11. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its new ... GLOBAL MARKETS , the global market for digital polymerase ... 2013. This is estimated to grow to $490 billion ... (CAGR) of 28.6%. , New digital PCR technology has ... the broader PCR field. The opportunities presented by this ...
(Date:7/11/2014)... AZ (PRWEB) July 11, 2014 ... device company specializing in the soft tissue reconstruction ... All-Suture Anchor System for surgeries involving the shoulder ... fixation through a novel, inserter-controlled deployment method. The ... to partial deployment, anchor pull-out, or anchor displacement ...
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... Angeles, CA (PRWEB) July 10, 2014 ... and Bioanalytical techniques during 18-20 August, 2014 at Double ... critically review the recent developments in Analytical & Bioanalytical ... the globe. , Speaking on this occasion, Dr. Srinubabu ... Analytica Acta conference is a remarkable one in ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... Access to ZFN Technology To Potentially Improve ... ... SGMO ) today announced that it has entered into a,second ... to include additional targets for potential improvement,of production cell lines using ...
... and Marburg viruses using virus-like particles (VLPs) ... Researchers from the U.S. Army Medical Research Institute ... (Feb. 26) at the 2008 ASM Biodefense and ... VLPs are one of the most promising candidates ...
... revenue growth ... 2007 Highlights: * Product revenues ... pulse oximeter units increase 20% to 116,300 units, IRVINE, Calif., Feb. 26 ... & Low Perfusion pulse oximetry, today announced its financial,results for both the quarter ...
Cached Biology Technology:Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production 2Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production 3Combination vaccine protects monkeys from ebola and Marburg viruses 2Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 2Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 3Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 4Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 5Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 6Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 7Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 8Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 9Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 10Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 11Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 12
(Date:7/11/2014)... . X-ray ... of X-rays through a specimen instead of attenuation resulting ... often of much higher quality than those based on ... Pfeiffer are particularly interested in developing new approaches for ... imaging. One main goal is to make this method ...
(Date:7/11/2014)... 2014, Shenzhen, China Researchers from Salk Institute for ... first time evaluated the safety and reliability of ... developed a new method, TALEN-HDAdV, which could significantly ... cell (hiPSC). This study published online in ... foundation for stem cell-based gene therapy. , The ...
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... Cold Spring Harbor, NY Every gardener knows the look ... earthy smell, and the sweet juicy flavor are hard to ... from the backyard garden variety, which can grow endlessly under ... will be canned for sauces and juice are harvested from ...
... Various medications have been developed to treat neurodegenerative ... gaining widespread interest such disorders. Brain Research Institute ... Crneci, found that the protein p300, which is ... during specific learning tasks, is at the same ...
... the Boston area, Mexico, and Norway have completed a ... populations. The study identified recurrent genetic mutations not previously ... which targeted treatments have been approved for other forms ... role human papillomavirus (HPV) plays in the development of ...
Cached Biology News:Genetic discovery points the way to much bigger yields in tomato, other flowering food plants 2International team completes systematic, genomic study of cervical cancer 2International team completes systematic, genomic study of cervical cancer 3International team completes systematic, genomic study of cervical cancer 4International team completes systematic, genomic study of cervical cancer 5
... The new Adept CE 4100 high ... superb flow precision, with software drive compensation, ... from 0.001-10mL/min are selectable in 0.001mL steps. ... are inert and bio-compatible., Pumps may be ...
... angle system, 220-240 V, is used to resolve ... fragments by pulsed field gel electrophoresis (PFGE). The ... pump, 14 x 13 cm casting stand with ... thick comb, screened cap, disposable plug molds, 12 ...
... Immuno-Blot PVDF membrane and filter paper ... PVDF membrane and two sheets of thick ... blotting membrane and filter paper sandwich. These ... high binding capacity immunoblotting fit Ready Gel-sized ...
... fromStreptomyces griseolusthat inhibits protein synthesis. Acts ... eukaryote ribosomes. Reported to induce apoptosis ... promyelocytic leukemia cells, Jurkat cells, ventricular ... intracellular signals and immediate early gene ...
Biology Products: